# TG Therapeutics, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/TG Therapeutics, Inc). ## Overview TG Therapeutics is a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases and related immune-mediated disorders. Its commercial portfolio is anchored by BRIUMVI for relapsing forms of multiple sclerosis, alongside a research pipeline and external business development activities such as in-licensing and partnerships. ## Products & services • BRIUMVI (ublituximab-xiiy) for relapsing forms of MS • Development pipeline for B-cell disease therapies • In-licensing and partnership evaluation • Acquisition and investment opportunities in complementary assets - **Commercial product** (100%) — BRIUMVI, an anti-CD20 monoclonal antibody approved for relapsing forms of multiple sclerosis. - **Pipeline development** (0%) — Research-stage programs and product candidates targeting B-cell diseases and immune disorders. - **Business development** (0%) — In-licensing, partnership, acquisition, and investment activities to expand the portfolio. - BRIUMVI (ublituximab-xiiy) for relapsing forms of MS - Development pipeline for B-cell disease therapies - In-licensing and partnership evaluation - Acquisition and investment opportunities in complementary assets ## Customers TG Therapeutics sells primarily into the multiple sclerosis treatment market, where prescribing physicians and healthcare systems determine adoption. The end users are adult patients with relapsing forms of MS, while access depends heavily on payors, specialty pharmacies, and infusion-site channels. For pipeline assets, the company’s counterparties are typically research, licensing, or commercialization partners rather than direct patients. - **Multiple sclerosis prescribers** (primary) — Neurologists and MS specialists who prescribe BRIUMVI based on efficacy, safety, and administration profile. - **MS patients** (primary) — Adults with relapsing forms of MS who receive treatment through physician-directed care and infusion settings. - **Healthcare payors** (primary) — Commercial and government payors that determine formulary access, reimbursement, and patient affordability. - **Commercial partners** (secondary) — Licensing and collaboration counterparties for development, commercialization, and asset expansion. - Neurologists treating adult patients with relapsing forms of MS - Healthcare systems and infusion providers administering BRIUMVI - Patients with clinically isolated syndrome, RRMS, or active SPMS - Payers and reimbursement decision-makers influencing access - Licensing and collaboration partners for pipeline expansion ## Geography TG Therapeutics is headquartered in the United States and commercializes BRIUMVI in the U.S. and selected international markets through regulatory approvals outside the U.S. The company relies on a global outsourced manufacturing network, including Samsung Biologics and FUJIFILM Diosynth Biotechnologies, so its operating footprint extends beyond its home market even though sales are centered in the U.S. Geography matters because reimbursement, regulatory approval, and supply-chain execution differ across markets. - Headquartered in the United States - BRIUMVI is approved in the U.S. for relapsing forms of MS - Also approved by several regulators outside the U.S. - Manufacturing is outsourced to third-party global partners - Supply chain spans contract manufacturers in Asia and Europe ## Strategy TG Therapeutics is focused on expanding BRIUMVI adoption in multiple sclerosis while advancing a pipeline in B-cell diseases. It also seeks to broaden its portfolio through in-licensing, partnerships, acquisitions, and investment opportunities that can complement its commercial infrastructure. - **Commercialize BRIUMVI in MS** (short-term) — The marketed product is the core revenue driver and the basis for the company's commercial platform. - **Build pipeline depth in B-cell diseases** (medium-term) — Pipeline assets can diversify the company beyond a single commercial product. - **Pursue external business development** (medium-term) — In-licensing and partnerships can add assets without building everything internally. - Grow BRIUMVI adoption in the MS market - Differentiate through clinical and commercial execution - Advance pipeline assets in B-cell diseases - Use external innovation to expand the portfolio - Maintain outsourced manufacturing flexibility ## Risks TG Therapeutics faces the typical risks of a commercial-stage biotech company: market acceptance, payer coverage, regulatory scrutiny, and competition from larger pharmaceutical companies. Its reliance on third-party manufacturing and a small number of approved products also creates concentration and supply-chain risk, while future pipeline value depends on successful development and approval outcomes. - **Limited market acceptance of approved products** [high] — Sales depend on physician, patient, and payor adoption in a crowded MS market. - **Competition in multiple sclerosis** [high] — Competing anti-CD20 therapies and new mechanisms may reduce utilization of BRIUMVI. - **Dependence on third-party manufacturers** [high] — The company does not own manufacturing facilities and relies on contract partners for supply. - **Regulatory and reimbursement pressure** [medium] — Drug pricing, coverage decisions, and healthcare reform can reduce realized revenue. - **Clinical development and approval risk** [medium] — Pipeline assets may not demonstrate sufficient efficacy, safety, or commercial value. - BRIUMVI adoption may be slower than expected - Payor coverage and reimbursement can limit access - Competition from anti-CD20 and new MS therapies is intense - Third-party manufacturing creates supply and quality risk - Pipeline programs may fail in development or approval ## Accounting The most important accounting issues are revenue recognition for product sales, which can be affected by rebates, chargebacks, discounts, and returns in the pharmaceutical channel. Investors should also watch estimates tied to outsourced manufacturing, clinical development costs, and any impairment or valuation judgments for acquired or in-licensed intangible assets. - **Net product revenue deductions** — BRIUMVI sales - **Inventory and supply-chain accruals** — Cost of sales and working capital - **Clinical and development expense recognition** — Research and development expense - **Intangible asset valuation** — Balance sheet and earnings - Net product revenue depends on rebates, discounts, and chargebacks - Channel inventory and returns can affect quarterly revenue timing - Outsourced manufacturing creates accrual and inventory valuation estimates - Clinical development spending is expensed as incurred - Acquired intangibles may require impairment or fair value judgments --- *Last updated: 2026-09-24T11:08:02.035103+00:00*